Close Menu

cell-free DNA

The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.

The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.

MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.

The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.

Guardant will help MD Anderson develop new assays and conduct clinical studies, and physicians will be able to order the company's test through an EMR system. 

Milenia will exclusively offer the test to patients through its network of 12 diagnostic centers in Mexico, and will also make future assays available.

The collaborators will explore the use of cell-free DNA for preimplantation genetic testing. 

The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.